Blueprint Medicines Corp expected to post a loss of $2.04 a share - Earnings Preview

Blueprint Medicines

13/02/2024 13:53

* Blueprint Medicines Corp  BPMC.OQ   BPMC.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
15 for the period ending December 31 2023
    * The Cambridge Massachusetts-based  company is expected to
report
a 72.2% increase in revenue to $66.797 million from $38.78
million a year ago, according to the mean estimate from 17
analysts, based on LSEG data. (Majority is on Total Revenue
basis)
    * ​LSEG's mean analyst estimate for Blueprint Medicines Corp
is
for a loss of $2.04 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $94.00​, above​ its last closing price
of $77.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -2.33       -2.37      -2.20     Beat    7.1
 Jun. 30 2023  -2.54       -2.54      -2.19     Beat    13.8
 Mar. 31 2023  -2.69       -2.67      -2.15     Beat    19.5​
 Dec. 31 2022  -2.65       -2.65      -2.65     Met     0
 ​​Sep.        -2.46       -2.49      -2.23     Beat    10.3
 30 2022                                                
 Jun. 30 2022  -2.25       -2.23      -2.68     Missed  -20.3​
 Mar. 31 2022  -1.78       -1.86      -1.79     Beat    3.9
 Dec. 31 2021  -2.48       -1.65      -5.40     Missed  -228.1
 This summary was machine generated February 13 at 13:53 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)